Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | June 01, 2026 | June 03, 2026 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | May 21, 2024 | May 23, 2024 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 05, 2025 | June 10, 2025 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,582 |
Ending reported balance
After 2026-06-01 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-06-01 · Exercise / conversion · Acquired 3,830 · Balance 5,412 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. Row 2 · 2026-06-01 · Sale · Disposed 921 · Balance 4,491 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-06-01 · Sale · Disposed 1,175 · Balance 3,316 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-06-01 · Sale · Disposed 1,222 · Balance 2,094 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-06-01 · Sale · Disposed 495 · Balance 1,599 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-06-01 · Sale · Disposed 17 · Balance 1,582 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.20 · Expires 2026-06-03 | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-01 · Exercise / conversion · Disposed 3,830 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F7: This stock option was fully vested and exercisable as of June 3, 2017. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 27,900 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 27,900 F6: The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.
F7: This stock option was fully vested and exercisable as of June 3, 2017.
BIOMARIN PHARMACEUTICAL INC
Report date May 21, 2024 · Filed May 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,750 |
Reported balance
After 2024-05-21 transaction · row 1
1 source rowRow 1 · 2024-05-21 · Grant · Acquired 4,720 · Balance 49,750 F1: Restricted stock units granted on May 21, 2024. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on May 21, 2024. Price not applicable.
PLIANT THERAPEUTICS, INC.
Report date June 05, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2035-06-05 | Direct | 30,000 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 30,000 · Balance 30,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Tarsus Pharmaceuticals, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the David E.I. Pyott Trust | 9,575 |
Reported balance
After 2026-09-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 201 · Balance 9,575 F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F2: Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 605 |
Reported balance
After 2026-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-15 · Exercise / conversion · Disposed 201 · Balance 605 F3: Each RSU represents a contingent right to receive one share of the Company's common stock. F4: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2: Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.
F3: Each RSU represents a contingent right to receive one share of the Company's common stock.
F4: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avery Dennison Corp
Report date April 23, 2020 · Filed April 24, 2020
Section 16 reporting ended · disclosed 2020-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,684 |
Reported balance
After 2020-04-23 transaction · row 1
1 source rowRow 1 · 2020-04-23 · Exercise / conversion · Acquired 1,414 · Balance 18,684 |
| 2019 Director RSU AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-05-01 | Direct | 0 |
Reported balance
After 2020-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-23 · Exercise / conversion · Disposed 1,414 · Balance 0 F1: Discretionary vesting on last day of Reporting Person's membership on the Issuer's board of directors given service for nearly entire one-year term for which he had been most recently elected. |
| Common Stock Units - DDECPSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 1988-08-08 | IndirectDDECP | 52,267.5096 |
Reported balance
Holding disclosure · report date 2020-04-23 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 52,267.5096 |
Filing footnotes · ownership attribution and instrument terms
F1: Discretionary vesting on last day of Reporting Person's membership on the Issuer's board of directors given service for nearly entire one-year term for which he had been most recently elected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:47 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001051578-26-000010 · wk-form4_1789678066.xml · derivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 605 Underlying: Common Stock · 201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. F4 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:47 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001051578-26-000010 · wk-form4_1789678066.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the David E.I. Pyott Trust Disclosed balance after: 9,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F2 · balance_after: Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 806 | $0.00 | $0.00 |
DisclosureSEC source: 0001051578-26-000008 · wk-form4_1782765056.xml · derivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 806 Underlying: Common Stock · 806 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. F4 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001051578-26-000008 · wk-form4_1782765056.xml · derivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,417 Underlying: Common Stock · 2,417 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 3,837 | $0.00 Strike: $64.34 | $0.00 |
DisclosureSEC source: 0001051578-26-000008 · wk-form4_1782765056.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,837 Underlying: Common Stock · 3,837 shares Expires 2036-06-24 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,830 | $0.00 Strike: $70.20 | $0.00 |
DisclosureSEC source: 0001178670-26-000048 · form4.xml · derivative · entry 8 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,830 shares Expires 2026-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F7 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 3, 2017. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 17 | $302.65 | $5,145.05 |
DisclosureSEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 6 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,582 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 495 | $300.72 | $148,856.40 |
DisclosureSEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 5 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,599 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,222 | $299.87 | $366,441.14 |
DisclosureSEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 4 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,094 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,175 | $298.91 | $351,219.25 |
DisclosureSEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,316 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 921 | $297.71 | $274,190.91 |
DisclosureSEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,491 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 3,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (Right to Buy) · Derivative | 1,441 | $0.00 Strike: $298.48 | $0.00 |
DisclosureSEC source: 0001178670-26-000039 · form4.xml · derivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,441 Underlying: Common Stock · 1,441 shares Expires 2036-05-20 F3 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:14 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0001178670-26-000039 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,582 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| April 24, 2026 Filed Apr 28, 2026 20:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 1,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001051578-26-000006 · wk-form4_1777407836.xml · derivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,383 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vested in full on April 24, 2026, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs vested in full on April 24, 2026, subject to the Reporting Person's continuous service. Read SEC document |
| April 24, 2026 Filed Apr 28, 2026 20:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 1,383 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001051578-26-000006 · wk-form4_1777407836.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:35 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 3,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001051578-26-000004 · wk-form4_1771623346.xml · derivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,729 Underlying: Common Stock · 3,729 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:35 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 5,893 | $0.00 Strike: $63.27 | $0.00 |
DisclosureSEC source: 0001051578-26-000004 · wk-form4_1771623346.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,893 Underlying: Common Stock · 5,893 shares Expires 2036-02-17 F1 · derivative.exercise_date: The option shares will vest in three equal annual installments on February 18th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| June 05, 2025 Filed Jun 10, 2025 00:43 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001746473-25-000126 · wk-form4_1749516194.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,558 | $0.00 Strike: $258.35 | $0.00 |
DisclosureSEC source: 0001735276-25-000063 · edgardoc.xml · derivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2035-05-08 F3 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000063 · edgardoc.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 7,440 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-25-000040 · edgardoc.xml · derivative · entry 4 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,440 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 5, 2024. The options exercised and sold by the reporting person were due to expire on December 18, 2025. F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 18, 2016. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,440 | $299.00 | $2,224,560.00 |
DisclosureSEC source: 0001735276-25-000040 · edgardoc.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 5, 2024. The options exercised and sold by the reporting person were due to expire on December 18, 2025. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 7,440 | $88.95 | $661,788.00 |
DisclosureSEC source: 0001735276-25-000040 · edgardoc.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 5, 2024. The options exercised and sold by the reporting person were due to expire on December 18, 2025. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 17,560 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · derivative · entry 10 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,440 Underlying: Common Stock · 17,560 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. F5 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 18, 2018. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 7,470 | $0.00 Strike: $71.99 | $0.00 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · derivative · entry 9 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,780 Underlying: Common Stock · 7,470 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 2, 2018. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 7,420 | $0.00 Strike: $70.20 | $0.00 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · derivative · entry 8 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,830 Underlying: Common Stock · 7,420 shares Expires 2026-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 3, 2017. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,470 | $222.00 | $1,658,340.00 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 6 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,420 | $221.00 | $1,639,820.00 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 5 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,606 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 17,560 | $220.00 | $3,863,200.00 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 4 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,026 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 7,470 | $71.99 | $537,765.30 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 7,420 | $70.20 | $520,884.00 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 17,560 | $88.95 | $1,561,962.00 |
DisclosureSEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023. Read SEC document |
| June 13, 2024 Filed Jun 18, 2024 00:16 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 26,764 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001746473-24-000105 · wk-form4_1718669756.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,764 Underlying: Common Stock · 26,764 shares Expires 2034-06-13 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:36 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000110 · wk-form4_1716500181.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,750 F1 · price: Restricted stock units granted on May 21, 2024. Price not applicable. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,228 | $0.00 Strike: $151.22 | $0.00 |
DisclosureSEC source: 0001735276-24-000055 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,228 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 21:24 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $23.09 | $0.00 |
DisclosureSEC source: 0001209191-23-035538 · doc4.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| May 23, 2023 Filed May 24, 2023 22:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031977 · doc4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,030 F1 · price: Restricted stock units granted on May 23, 2023. Price not applicable. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $189.87 | $0.00 |
DisclosureSEC source: 0001735276-23-000068 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,454 Underlying: Common Stock · 3,454 shares Expires 2033-05-18 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000018 · edgardoc.xml · derivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 136 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F3 · derivative.exercise_date: This award vested on February 23, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: This award vested on February 23, 2023, the first anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000018 · edgardoc.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:22 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001567619-22-013200 · doc1.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters beginning October 1st and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 16, 2022 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document |
| May 24, 2022 Filed May 27, 2022 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011800 · doc1.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,840 F1 · price: Restricted stock units granted on May 24, 2022. Price not applicable. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000055 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000028 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 4,032 | $0.00 Strike: $171.95 | $0.00 |
DisclosureSEC source: 0001735276-21-000073 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2031-07-14 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 00:49 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 13,286 | $0.00 Strike: $28.20 | $0.00 |
DisclosureSEC source: 0001209191-21-044180 · doc4.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,286 Underlying: Common Stock · 13,286 shares Expires 2021-06-28 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 00:14 UTC Amendment | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 13,286 | $0.00 Strike: $28.20 | $0.00 |
DisclosureSEC source: 0001209191-21-044628 · doc4a.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,286 Underlying: Common Stock · 13,286 shares Expires 2031-06-28 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document |
| May 25, 2021 Filed May 28, 2021 00:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011320 · doc1.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,860 F1 · price: Restricted stock units granted on May 25, 2021. Price not applicable. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 23:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 26,573 | $0.00 Strike: $27.71 | $0.00 |
DisclosureSEC source: 0000899243-21-001875 · doc4.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,573 Underlying: Common Stock · 26,573 shares Expires 2031-01-11 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 12, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.